Description

Buy Authentic AOD-9604+CJC-1295+Ipamorelin 6/3/3 mg Online

AOD-9604+CJC-1295+Ipamorelin is a research-use-only peptide blend supplied for controlled laboratory workflows, multi-compound documentation review, and analytical characterization. This blend is manufactured under rigorous quality standards to support consistency, traceability, and batch-specific verification for qualified laboratory settings.

What AOD-9604+CJC-1295+Ipamorelin 6/3/3 mg is:

This is a research chemical vial combining three synthetic peptides. AOD-9604 is a 16-amino-acid fragment of human growth hormone, residues 176-191, modified with a tyrosine at the N-terminus. CJC-1295 is a long-acting GHRH analog with a DAC modification. Ipamorelin is a pentapeptide GH secretagogue that acts on the ghrelin receptor. The “6/3/3 mg” indicates 6mg AOD-9604, 3mg CJC-1295, 3mg Ipamorelin per vial. All are sold “for research use only” and are not FDA-approved drugs.

Key Product Details Of AOD-9604+CJC-1295+Ipamorelin 6/3/3 mg

• Manufactured in accordance with rigorous quality standards to support ≥99% purity, as reflected in batch-specific documentation where available.
• Every batch is third-party analyzed for identity, assay/potency, and sterility documentation where applicable.
• Supplied in lyophilized powder form to help preserve stability throughout transport and storage.
• Produced with lot-level traceability to support research documentation and laboratory recordkeeping.
• Formulated as a multi-compound research blend containing AOD-9604, CJC-1295, and Ipamorelin.

Research Documentation Context

• Supports review of multi-compound blend composition in controlled laboratory settings.
• Provides batch-specific identity and purity documentation for research review.
• Allows lot-level traceability across laboratory documentation workflows.
• Supports comparison of product labeling, analytical documentation, and storage information during research planning.
• Assists researchers in evaluating component disclosure within a clearly identified peptide blend.

Specifications and Documentation

• Blend Composition: AOD-9604 + CJC-1295 + Ipamorelin.
• Certificate of Analysis: Available with batch-specific documentation where applicable.
• Material Safety Data Sheet: Coming Soon.
• Handling and Storage Instructions: Coming Soon.
• Product Form: Lyophilized powder.
• Purity Specification: ≥99% purity.
• Intended Use: Laboratory research use only.

AOD-9604 + CJC-1295 + Ipamorelin is intended strictly for laboratory research use only. This product is not intended for human or animal consumption, therapeutic use, diagnostic use, clinical use, veterinary use, or as a food, drug, cosmetic, dietary supplement, or household product.

How researchers study this triple blend

In preclinical models, each peptide is used to probe different pathways. AOD-9604 is studied for lipolysis and fat metabolism in adipocytes, based on early research into the fat-reducing domain of hGH. CJC-1295 is used to study sustained GHRH receptor activation and GH pulse frequency. Ipamorelin is used to study selective ghrelin receptor agonism with minimal cortisol/ACTH release vs older GHRPs. Labs combine them to investigate GH axis stimulation + direct lipolytic signaling in animal models.

 Why the blend gets research attention

The research rationale is targeting fat metabolism through multiple mechanisms. CJC-1295 + Ipamorelin synergize to amplify pulsatile GH release — GHRH signal + ghrelin receptor sensitization. AOD-9604 is added to study direct effects on adipose tissue independent of full hGH. None of these peptides have completed Phase 3 human trials. AOD-9604 was tested in 6 human trials for obesity ∼20 years ago but never approved. CJC-1295 and Ipamorelin have no FDA approval.

Form, purity & handling

The blend comes as a white lyophilized powder in a sealed sterile vial. Reputable suppliers provide a COA with HPLC and mass spec for all three peptides, usually >95% purity each. CJC-1295 with DAC is more stable; AOD-9604 and Ipamorelin are still sensitive to heat, light, and moisture. Ship cold, store at -20°C or -80°C after reconstitution. No pharmaceutical-grade combo product exists.

Legal + safety status

None of these peptides are FDA-approved for medical use. They’re all “for research use only, not for human consumption.” No established human dosing for the combo, no drug-interaction data, no long-term safety studies. All three are banned by WADA for athletes. GH axis manipulation carries theoretical risks: insulin resistance, edema, paresthesia, and promotion of existing tumors. AOD-9604’s early trials showed poor efficacy vs placebo for weight loss.

Bottom line

*AOD-9604 + CJC-1295 + Ipamorelin 6/3/3 mg* is a research tool used to study lipolysis, GHRH signaling, and ghrelin receptor agonism in the lab. While obesity and GH deficiency are real medical conditions with FDA-approved treatments, this triple blend has no regulatory approval, human safety profile, or proven clinical benefit. For weight management, body composition, or hormone concerns, talk to a licensed healthcare provider about evidence-based diagnostics and FDA-approved therapies.